Video interview: Regulatory issues key for life sciences in Brexit debate

With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Speaking at the Life Sciences Patent Network North America, an event hosted by LSIPR in Boston in June, Dagg stated that companies need to be able to continue business as usual “from day one of Brexit”.

She was speaking on a panel discussing the impact Britain’s departure could have on the industry.

Dagg added that despite early optimism about regulation change, the first step should be to ensure companies can continue as normal.